Laman UtamaEVGN • NASDAQ
add
Evogene Ltd
Tutup sebelumnya
$1.06
Julat hari
$1.06 - $1.09
Julat tahun
$0.93 - $2.42
Permodalan pasaran
9.24J USD
Bilangan Purata
48.31K
Nisbah P/E
-
Hasil dividen
-
Pertukaran utama
NASDAQ
Berita pasaran
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
| (USD) | Sep 2025info | Perubahan T/T |
|---|---|---|
Hasil | 312.00K | -82.63% |
Perbelanjaan pengendalian | 2.88J | -64.76% |
Pendapatan bersih | 3.87J | 150.77% |
Margin untung bersih | 1.24K | 392.27% |
Pendapatan bagi setiap syer | -0.46 | 64.51% |
EBITDA | -2.44J | 64.22% |
Kadar cukai berkesan | -0.04% | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
| (USD) | Sep 2025info | Perubahan T/T |
|---|---|---|
Pelaburan tunai dan jangka pendek | 15.96J | -20.02% |
Jumlah aset | 26.09J | -34.97% |
Jumlah liabiliti | 8.83J | -68.31% |
Jumlah ekuiti | 17.25J | — |
Syer tertunggak | 8.72J | — |
Harga kepada buku | 8.15 | — |
Pulangan pada aset | -22.70% | — |
Pulangan pada modal | -39.13% | — |
Aliran Tunai
Perubahan bersih dalam tunai
| (USD) | Sep 2025info | Perubahan T/T |
|---|---|---|
Pendapatan bersih | 3.87J | 150.77% |
Tunai daripada operasi | -3.33J | 32.37% |
Tunai daripada pelaburan | 10.91J | 441.12% |
Tunai daripada pembiayaan | -10.34J | -318.34% |
Perubahan bersih dalam tunai | -2.70J | -247.46% |
Aliran tunai bebas | -385.62K | -131.18% |
Perihal
Evogene is a computational chemistry company based in Israel, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries. At the core of its technology is ChemPass AI, a proprietary generative AI engine that enables the design of novel, highly potent small molecules optimized across multiple critical parameters. This powerful platform significantly improves success rates while reducing development time and costs. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products driven by the integration of scientific innovation with real-world industry needs.
In 2024, the company began collaborating with Google Cloud to develop an AI-powered generative model aimed at discovering small molecules for drug development and sustainable agriculture. Wikipedia
CEO
Diasaskan
1999
Tapak web
Pekerja
117